On Wednesday, Nutanix Cl A received a positive adjustment to its Relative Strength (RS) Rating, from 78 to 81.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the top-performing stocks often have an 80 or better RS Rating in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Nutanix Cl A is not currently near a potential buying area. See if the stock goes on to build a base that could spark a new run.
Nutanix Cl A saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 13% to 45%. Revenue rose from 11% to 16%.
The company holds the No. 49 rank among its peers in the Computer Software-Enterprise industry group. Datadog, Enfusion and Klaviyo are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
